Background: Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer.
Methods: Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible. The patients underwent thoracic radiotherapy (45 Gy, 1.5 Gy bid, 30 fractions for 3 weeks) delivered concurrently with etoposide (100 mg/m2 iv, days 1-3) and cisplatin dose escalating from the two levels ( 70 mg/m2 and 75 mg/m2 on d1). The primary endpoints were hematologic toxicities during treatment. The secondary endpoints were non-hematologic toxicities, overall survival (OS) and progression-free survival (PFS). According to Common Terminology Criteria for Adverse Events 4.0 (CTC-AE 4.0), maximum tolerant dosage (MTD) was defined as the highest safely tolerated dose at which no more than one patient out of six experiences dose-limiting toxicity (Grades 4 hematologic), with the next higher dose having at least two out of six patients experience dose-limiting toxicity.
Results: From January 2013 to August 2016, 20 patients were enrolled in this study. The median age was 49.5 (30-68). After the first 6 patients were enrolled in Arm 1 (70 mg/m2 on d1), one patient had Grade 4 neutropenia. Another 14 patients were enrolled in Arm 2 (75 mg/m2 on d1), one patient had Grade 4 neutropenia. The MTD was determined to be etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). 4 patients had ≥Grade 3 neutropenia and 1 patients had ≥Grade 3 acute esophagitis in Arm 1. 10 patients had ≥Grade 3 neutropenia and no patient had ≥Grade 3 acute esophagitis in Arm 2. All patients with a median follow-up time was 9.0 months, median OS and PFS were not achieved, 1-year OS and PFS were 91% and 61%, respectively.
Conclusions: The MTD of RT with concurrent chemotherapy of EP regimen for patients with LS-SCLC was etoposide (100 mg/m2 iv, d1-d3) and cisplatin dose (75 mg/m2 on d1). .
背景与目的 加速超分割放疗（每日两次方案）联合EP方案同步化疗是美国国立综合癌症网络（National Comprehensive Cancer Network, NCCN）指南推荐的局限期小细胞肺癌的标准治疗方式，但国人对EP方案标准化疗剂量耐受性尚不明确。本研究旨在探讨局限期小细胞肺癌同步放化疗EP方案的最大耐受剂量。方法 研究纳入病理证实的局限期小细胞肺癌患者，进行加速超分割放疗同步EP方案（依托泊苷+顺铂）化疗，放疗处方剂量为45 Gy/30 f，1.5 Gy/f，每日两次，同一日两次放疗间隔时间≥6 h，5天/周，共3周完成。化疗方案采用依托泊苷联合顺铂，每21天为1周期，具体依托泊苷100 mg/m2，d1-d3，顺铂采用剂量递增的方式（第1组为70 mg/m2 d1，第2组为75 mg/m2 d1）。主要观察指标为治疗期间的血液学毒性。次要观察指标为非血液学毒性和1年总生存期（overall survival, OS）、无进展生存期（progression free survival, PFS）。根据不良事件常用术语评定标准（Common Terminology Criteria for Adverse Events, NCI-CTCAE）4.0，最大耐受剂量设定为6例患者中不超过1例患者出现剂量限制毒性（4级血液学毒性）的剂量，同时下一剂量组6例患者至少2例出现剂量限制性毒性。结果 研究共纳入20例局限期小细胞肺癌患者，平均年龄49.50（30-68）岁。第1组入组6例患者，1例患者出现4度中性粒细胞减少；后第2组入组14例患者，1例患者出现4度中性粒细胞减少。其中，第1组有4例患者出现≥3度血液学毒性，1例患者出现3度以上放射性食管炎；第2组有10例患者出现≥3度血液学毒性，无患者出现3度以上放射性食管炎。中位随访9.0个月（3.2个月-36.2个月），1年OS、PFS分别为91%、62%。结论 局限期小细胞肺癌患者采用加速超分割放疗联合EP方案化疗将顺铂剂量递增至75 mg/m2是安全的，其有效性还需要进一步扩大样本量和随访更长的时间来证实。.